Afatinib in EGFR TKI-naive patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

被引：0

作者：

Passaro, A. ^{[1
]}

Laktionov, K. K. ^{[2
]}

Poltoratskiy, A. ^{[3
]}

Egorova, I. ^{[4
]}

Hochmair, M. ^{[5
]}

Migliorino, M. R. ^{[6
]}

Metro, G. ^{[7
]}

Gottfried, M. ^{[8
]}

Tsoi, D. ^{[9
]}

Ostoros, G. ^{[10
]}

Rizzato, S. ^{[11
]}

Mukhametshina, G. Z. ^{[12
]}

Schumacher, M. ^{[13
]}

Novello, S. ^{[14
]}

Dziadziuszko, R. ^{[15
]}

Tang, W. ^{[16
]}

Clementi, L. ^{[17
]}

Cseh, A. ^{[18
]}

Kowalski, D. ^{[19
]}

De Marinis, F. ^{[1
]}

机构：

[1] European Inst Oncol, Milan, Italy

[2] Russian Acad Med Sci, Moscow, Russia

[3] Petrov Res Inst Oncol, St Petersburg, Russia

[4] Clin Oncol Dispensary, St Petersburg, Russia

[5] Otto Wagner Hosp, Vienna, Austria

[6] San Camillo Forlanini Hosp, Rome, Italy

[7] Santa Maria Misericordia Hosp, Perugia, Italy

[8] Tel Aviv Univ, Tel Aviv, Israel

[9] St John God Murdoch Hosp, Murdoch, WA, Australia

[10] Natl Koranyi Inst Pulmonol, Budapest, Hungary

[11] Azienda Sanit Univ Integrata, Udine, Italy

[12] Minist Hlth Republ Tatarstan, Kazan, Russia

[13] Ordensklinikum Elisabethinen, Linz, Austria

[14] Univ Turin, Turin, Italy

[15] Med Univ Gdansk, Gdansk, Poland

[16] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[17] Boehringer Ingelheim Italia SpA, Milan, Italy

[18] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria

[19] Oncol Ctr & Inst, Warsaw, Poland

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

115O

引用

页数：2

共 50 条

[1] Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
De Marinis, F.
Laktionov, K. K.
Poltoratskiy, A.
Egorova, I.
Hochmair, M.
Passaro, A.
Migliorino, M. R.
Metro, G.
Gottfried, M.
Tsoi, D.
Ostoros, G.
Rizzato, S.
Mukhametshina, G. Z.
Schumacher, M.
Novello, S.
Dziadziuszko, R.
Tang, W.
Clementi, L.
Cseh, A.
Kowalski, D.
ANNALS OF ONCOLOGY, 2019, 30
[2] A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
de Marinis, F.
Tu, H.
Laktionov, K. K.
Feng, J.
Poltoratskiy, A.
Zhao, J.
Egorova, I.
Tan, E-H.
Gottfried, M.
Lee, V.
Kowalski, D. M.
Yang, C-T.
Srinivasa, B. J.
Passaro, A.
Clementi, L.
Tang, W.
Huang, D. C-L.
Cseh, A.
Zhou, C.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30 : 600 - 600
[3] A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naive Patients with EGFRm plus NSCLC: An Interim Analysis
De Marinis, F.
Laktionov, K. K.
Poltoratskiy, A.
Egorova, I.
Hochmair, M. J.
Passaro, A.
Migliorino, M. R.
Metro, G.
Gottfried, M.
Tsoi, D.
Ostoros, G.
Rizzato, S.
Mukhametshina, G. Z.
Schumacher, M.
Novello, S.
Dziadziuszko, R.
Tang, W.
Clementi, L.
Cseh, A.
Kowalski, D.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S853 - S854
[4] A phase IIIb, open-label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis
Rosell, R.
Poltoratskiy, A.
Hochmair, M.
Laktionov, K. K.
Ramlau, R.
Alonso Garcia, M.
Skrickova, J.
Piovano, P. L.
Rizzato, S.
Bidoli, P.
Kowalski, D.
Clementi, L.
Cseh, A.
De Marinis, F.
ANNALS OF ONCOLOGY, 2019, 30
[5] A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naive Patients with EGFR Mutation-Positive NSCLC: Final Analysis
Wu, Y.
Tu, H.
Feng, J.
Shi, M.
Zhao, J.
Wang, Y.
Chang, J.
Wang, J.
Cheng, Y.
Zhu, J.
Tan, E.
Zhang, Y.
Lee, V.
Yang, C.
Su, W.
Lam, D. C.
Srinivasa, B.
Rajappa, S.
Ho, C.
Lam, K. C.
Hu, Y.
Bondarde, S. A.
Liu, X.
Pang, K.
Tian, Y.
Cseh, A.
Huang, D. C.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S679 - S680
[6] A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: An Interim Analysis
Wu, Y.
Tu, H.
Feng, J.
Shi, M.
Zhao, J.
Wang, Y.
Chang, J.
Wang, J.
Cheng, Y.
Zhu, J.
Tan, E.
Li, K.
Zhang, Y.
Lee, V.
Yang, C.
Su, W.
Lam, C. L.
Srinivasa, B.
Rajappa, S.
Ho, C.
Lam, K. C.
Hu, Y.
Bondarde, S. A.
Liu, X.
Fan, J.
Kuo, D.
Wang, Y.
Pang, K.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2214 - S2214
[7] Afatinib in EGFR TKI-Naive Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies
De Marinis, F.
Tu, H.
Laktionov, K. K.
Poltoratskiy, A.
Zhao, J.
Egorova, I.
Tan, E.
Gottfried, M.
Lee, V.
Kowalski, D.
Yang, C.
Srinivasa, B.
Passaro, A.
Clementi, L.
Tang, W.
Huang, D. C.
Cseh, A.
Zhou, C.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S579 - S580
[8] Afatinib in EGFR TKI-Naive Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
Passaro, Antonio
de Marinis, Filippo
Tu, Hai-Yan
Laktionov, Konstantin K.
Feng, Jifeng
Poltoratskiy, Artem
Zhao, Jun
Tan, Eng Huat
Gottfried, Maya
Lee, Victor
Kowalski, Dariusz
Yang, Cheng Ta
Srinivasa, B. J.
Clementi, Laura
Jalikop, Tejaswini
Huang, Dennis Chin Lun
Cseh, Agnieszka
Park, Keunchil
Wu, Yi-Long
FRONTIERS IN ONCOLOGY, 2021, 11
[9] Afatinib in EGFR TKI-naive patients with EGFR mutation-positive (EGFRm plus ) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study
de Marinis, F.
Laktionov, K. K.
Poltoratskiy, A.
Egorova, I.
Hochmair, M.
Passaro, A.
Migliorino, M. R.
Metro, G.
Gottfried, M.
Tsoi, D.
Ostoros, G.
Rizzato, S.
Mukhametshina, G. Z.
Schumacher, M.
Novello, S.
Tang, W.
Clementi, L.
Cseh, A.
Kowalski, D. M.
ANNALS OF ONCOLOGY, 2019, 30
[10] A phase IIIb open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm1) NSCLC: Exploratory biomarker analysis
Wang, J.
Zhao, J.
Bai, H.
Wang, X.
Wang, Y.
Duan, J.
Chen, H.
Meng, S.
Tian, Y.
Huang, D. C-L.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →